Allakos Inc. - Common Stock (ALLK)
Frequently Asked Questions About Allakos Inc. - Common Stock (ALLK)
How can investors stay updated on Allakos Inc.'s developments?
Investors can stay updated on Allakos Inc. by following the company's official website, subscription to investor relations newsletters, and monitoring financial news outlets for press releases, earnings calls, and updates from clinical trials that affect the company’s operations and stock performance.
How does Allakos approach drug development?
Allakos adopts a science-driven approach to drug development, focusing on preclinical research followed by rigorous clinical trials. The company emphasizes understanding the underlying mechanisms of diseases to create targeted therapies that can safely and effectively address patient needs.
How is eosinophilic esophagitis treated?
Eosinophilic esophagitis (EoE) treatment typically involves dietary modifications, medication to reduce inflammation, and sometimes the use of specialized therapies like monoclonal antibodies. Allakos's lirentelimab has shown promise in clinical trials, potentially providing a new treatment option for EoE patients.
Is Allakos Inc. publicly traded?
Yes, Allakos Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'ALLK.' The company's IPO took place in 2018, allowing it to raise capital for ongoing clinical trials and research.
What are eosinophilic diseases?
Eosinophilic diseases are a group of illnesses characterized by elevated eosinophil levels and related inflammation in various tissues. These conditions can lead to significant symptoms and complications, impacting the quality of life of affected individuals, making targeted treatments, like those developed by Allakos, a crucial area of focus.
What are the main therapeutic areas Allakos is focusing on?
Allakos Inc. focuses primarily on allergic diseases and autoimmune disorders. Their research aims to develop treatments that target conditions driven by eosinophils and mast cells, including eosinophilic esophagitis, atopic dermatitis, and chronic rhinosinusitis.
What are the risks associated with investing in Allakos Inc.?
Investing in Allakos Inc. carries inherent risks typical of biotech companies, including regulatory uncertainties, clinical trial failures, and market competition. Investors must carefully consider these factors alongside the company's potential for innovative therapies and overall market dynamics.
What does Allakos Inc. do?
Allakos Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for allergic and autoimmune diseases by targeting immunomodulatory pathways. Specifically, the company is advancing its lead product candidate, lirentelimab, aimed at addressing various conditions resulting from eosinophil and mast cell activation.
What has been the market performance of Allakos Inc. shares?
The market performance of Allakos Inc. shares has experienced fluctuations like many biotechnology companies, influenced by clinical trial results, regulatory updates, and overall market trends. Shareholder sentiment and investor interest can impact the stock's valuation significantly, particularly around key data releases.
What is lirentelimab?
Lirentelimab is Allakos Inc.'s lead product candidate, a monoclonal antibody designed to inhibit the activity of mast cells and eosinophils, which are often involved in allergic and auto-inflammatory responses. The drug is being investigated for multiple indications, including potential treatments for eosinophilic gastrointestinal diseases.
What is the company’s vision for the future?
Allakos Inc. envisions a future where patients with eosinophil and mast cell-driven diseases have access to safe and effective treatment options. The company aims to leverage its scientific expertise to expand its pipeline and improve patient outcomes in underserved disease areas.
What is the status of Allakos's clinical trials?
Allakos Inc. is actively conducting multiple clinical trials for lirentelimab and other assets. These trials are at various stages of development, including Phase 2 and Phase 3 studies, with ongoing assessments of safety, efficacy, and patient outcomes in treating eosinophil-related conditions.
What partnerships or collaborations does Allakos have?
Allakos Inc. has sought collaborations and partnerships to enhance its research capabilities and expedite drug development. The company often engages with academic institutions and other biopharmaceutical companies to leverage expertise and resources in pursuing innovative therapies.
What recent milestones has Allakos achieved?
Allakos Inc. has achieved several milestones, including the successful initiation of clinical trials for lirentelimab and positive preliminary data from these studies. These accomplishments demonstrate the company's progress in developing its pipeline and advancing toward potential regulatory submissions.
What role do mast cells play in allergic responses?
Mast cells are immune cells that play a crucial role in the body's allergic response by releasing histamine and other mediators during allergic reactions. Their activation can lead to symptoms such as itching, swelling, and inflammation, which are targets for therapies like lirentelimab developed by Allakos.
When was Allakos Inc. founded?
Allakos Inc. was founded in 2012. The company has since focused on developing transformative medicines that can help patients suffering from serious diseases associated with the immune system.
Where is Allakos Inc. headquartered?
Allakos Inc. is headquartered in San Carlos, California. This location allows the company to be close to major biotech hubs and talent pools in the Science and Pharmaceuticals sectors.
Who are the key executives at Allakos Inc.?
As of my last update, key executives at Allakos include CEO Andrew R. Allen, M.D., who co-founded the company and has extensive experience in biopharmaceuticals. Other executive team members have backgrounds in drug development, operations, and finance, contributing to the company's strategic direction and mission.
What is the current price of Allakos Inc. - Common Stock?
The current price of Allakos Inc. - Common Stock is 0.3200
When was Allakos Inc. - Common Stock last traded?
The last trade of Allakos Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025
What is the market capitalization of Allakos Inc. - Common Stock?
The market capitalization of Allakos Inc. - Common Stock is 27.70M
How many shares of Allakos Inc. - Common Stock are outstanding?
Allakos Inc. - Common Stock has 86.56M shares outstanding.